Novartis drug from $3.2B deal succeeds in Phase 3

The latest stories trending on MedCity News.

Editor's Pick

Top Story Novartis Drug From $3.2B Deal Succeeds in Phase 3, 2024 FDA Filing Is Planned Novartis drug candidate atrasentan met the main goal of a pivotal study in the chronic kidney disease IgA nepropathy. It's one of two drugs added via the multi-billion dollar acquisition of Chinook Therapeutics; together with a homegrown therapeutic candidate, they give Novartis three different approaches to treat the rare disorder. Sponsored Content Harnessing the Power of Phone Interactions in Healthcare Presented by Parlance and MedCity News A human touch makes a significant difference in healthcare call interactions where an automation-dominant approach would fall short. Learn More. Sponsored Content Heard at HLTH 2023: MDLive Jonathan Salon, MDLIVE President, unveils MDLIVE's latest health coaching platform for chronic care support. Discover how MDLIVE's physician-driven primary care approach sets it apart, helping patients stay on track with personalized data between visits.  Watch Now

Featured News

How Tech is Saving Time for Specialty Pharmacies and Improving the Patient Experience In an interview, Surescripts' Clinical Product Advisor Cecelia Byers shared how the company is working to simplify prescribing and obtaining specialty medications. Health Exec: 97% of Healthcare Data Isn't Used The vast majority of healthcare data isn't used because it's difficult to work with, according to Beth Andrews, chief digital health officer of life sciences and healthcare at Dell Technologies. Andrews made these comments during a session at the MedCity News INVEST Digital Health conference. What Excites Health Execs About the Evolution of Employee Benefits Value-based care and data are areas to be excited about in the employee benefits space, executives shared during a panel discussion at the MedCity News INVEST Digital Health conference. Improving Hypertension Care for Underserved Populations with Remote Patient Monitoring Given the impact that RPM can have in addressing chronic conditions like hypertension, there is a distinct need for more funding to ensure all people have access to proven, digital health interventions. Regulations must be revamped so FQHCs, RHCs and CHCs are able to bill for RPM, much like other hospitals and health centers. How the Millions of Americans Losing Medicaid Can Stay Insured In all, up to 18 million Americans could lose Medicaid coverage through June 2024. Fortunately, the vast majority of these folks have a number of options for obtaining affordable coverage. They just have to know where to look. Merck KGaA Puts Up €160M for Drug to Rival DNA Damage Cancer Meds From AstraZeneca, Gilead A Hengrui drug that interferes with a cancer cell's DNA damage response is heading to Merck KGaA for €160 million up front and up to €1.4 billion tied to milestones. The deal also gives the German company an option to license a Hengrui antibody drug conjugate.

Resources

MedCity FemFwd Podcast: SCAN Inspired With Nancy Monk, Chief Operations Officer of SCAN Health Plan MedCity FemFwd, a podcast dedicated to discussing the breakthroughs and challenges in women's health, is back with another episode. This time, we are joined by Nancy Monk, chief operations officer of Medicare Advantage insurer SCAN Health Plan, to talk about the company's recent launch of SCAN Inspired, a Medicare Advantage plan designed for women.  Listen Now

MedCity News • PO Box 901 • New York, NY unsubscribe